Related Experiment Video
Updated: Jun 7, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients
Matteo Monami1, Claudia Colombi, Daniela Balzi
1Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Careggi Teaching Hospital, Florence, Italy.
Objective:
Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.
Research Design And Methods:
A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort.
Results:
During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25-0.85], P = 0.014 and 0.75 [0.39-1.45], P = 0.40, respectively).
Conclusions:
The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Psychoneuroimmunology: Diabetes and Cancer

